United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $535.99, for a total transaction of $5,091,905.00. Following the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at $21,714,562.87. This represents a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

United Therapeutics Stock Down 1.7%

UTHR stock opened at $526.66 on Wednesday. The stock has a market cap of $22.36 billion, a PE ratio of 19.44, a price-to-earnings-growth ratio of 1.79 and a beta of 0.58. The firm’s 50-day simple moving average is $555.07 and its 200 day simple moving average is $529.82. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same period in the previous year, the firm earned $6.63 earnings per share. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. Equities analysts forecast that United Therapeutics Corporation will post 26.63 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Torren Management LLC bought a new stake in United Therapeutics during the fourth quarter worth approximately $26,000. Activest Wealth Management boosted its stake in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC boosted its stake in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its position in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC acquired a new position in shares of United Therapeutics during the 4th quarter valued at $31,000. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on UTHR shares. Morgan Stanley set a $516.00 price objective on United Therapeutics in a research report on Thursday, May 7th. HC Wainwright raised their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. Bank of America reduced their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Finally, Royal Bank Of Canada increased their price target on United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $644.82.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.